针对成人失眠障碍的创新数字认知行为治疗 (dCBT-i):发展框架
Emilie Stern1,2, Severine Brune3, Stéphane Mouchabac4,5
1Centre ChronoS, GHU Paris psychiatrie & neurosciences, Paris, France.
JMIR human factors
|May 27, 2025
概括
开发了一个新的数字认知行为治疗失眠 (dCBT-i) 计划,以提高可访问性. 这种基于证据的数字治疗为失眠障碍提供了个性化的护理和可扩展的解决方案.
科学领域:
- 数字健康数字健康
- 行为科学 行为科学
- 睡眠医学 睡眠医学
背景情况:
- 慢性失眠影响高达15%的人口,构成重大健康挑战.
- 失眠的认知行为疗法 (CBT-i) 是一线治疗,但面临着可访问性问题.
- 数字化为提高医疗保健的可访问性和公平性提供了一个有希望的途径.
研究的目的:
- 开发一个基于证据的数字认知行为治疗失眠 (dCBT-i) 程序.
- 确保该计划适合整合到医疗保健系统.
- 在法国建立第一个用于治疗失眠的处方数字疗法.
主要方法:
- 该计划建立在经过验证的CBT-i原则和最新的科学研究基础上.
- 它结合了一个强大的,多组件的治疗方法.
- 功能包括标准化的初始评估和智能日常适应,以实现个性化治疗和数字表型.
主要成果:
- 创建了一个创新的数字解决方案,将科学严谨与实际应用融合在一起.
- 该计划的特点是标准化的初始评估.
- 通过智能算法实现动态个性化,使治疗适应个体患者的需求和进展.
结论:
- 开发的dCBT-i程序是数字医疗保健的一个重大进步.
- 它提供了一个可扩展的解决方案,以克服传统的CBT-i可访问性障碍.
- 计划进行进一步的临床研究,以评估有效性和优化实施.
更多相关视频
05:59Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
2.3K
06:23A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
Published on: September 22, 2020
5.3K
相关概念视频
Insomnia
81
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
81
Management of Insomnia
235
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
235
Cognitive Therapy
147
Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...
147
CNS Depressants: Barbiturates and Benzodiazepines
232
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
232
Rational Emotive Behavior Therapy
45
Cognitive-behavioral therapies (CBTs) are grounded in the belief that our thoughts profoundly influence our emotions and actions. Advocates of CBT emphasize three core assumptions: first, that cognitions are identifiable and measurable; second, that they are central to psychological functioning; and third, that irrational or maladaptive beliefs can be replaced with rational and adaptive ones. This transformative approach to therapy has paved the way for specific models such as Albert...
45
Sedatives and Hypnotics Drugs: Miscellaneous Agents
159
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
159
